{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:55:12Z","timestamp":1793890512066,"version":"4.8.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AI05419"],"award-info":[{"award-number":["AI05419"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AI058607"],"award-info":[{"award-number":["AI058607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["HHSN 272201100025C"],"award-info":[{"award-number":["HHSN 272201100025C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alberta Heritage Foundation for Medical Research, Canada Research Chair Program, Alberta Cancer Foundation, Calgary"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial compared hematopoietic stem cell transplant to CYC treatment in patients with early SSc with progressive skin and lung or kidney involvement. Here we describe lymphocyte phenotype abnormalities at study entry and the relation to prior DMARD therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Lymphocyte subsets (n\u2009=\u200926) measured by flow cytometry were compared in 123 heathy controls and 71 SCOT participants, including those given (n\u2009=\u200957) or not given (n\u2009=\u200914) DMARDs within 12\u2009months of randomization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with healthy controls, individuals with SSc showed significant reductions in central memory CD8 T cells, activated total and CD4 T cells, \u03b3\/\u03b4 T cells, memory B cells, myeloid and plasmacytoid dendritic cells and FOXP3+CD25+ Treg cells and increases in na\u00efve CD4 T cells, effector memory CD4 T cells and effector CD8 T cells. A greater bias towards a IL-4+ Th2\/T cytotoxic 2 (Tc2) phenotype based on the Th2:Th1 CD4 ratio and Tc2:Tc1 CD8 T cells was also found. Notably, no difference in any lymphocyte subset was observed between those given or not given prior DMARDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with early, severe SSc, significant lymphocyte subset abnormalities were observed. Prior treatment with immunosuppressive therapy did not impact the immunophenotype, suggesting that lymphocyte disturbances in scleroderma appeared to be due to the disease itself.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov (https:\/\/clinicaltrials.gov), NCT00114530.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keac015","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T04:43:15Z","timestamp":1643431395000},"page":"4155-4162","source":"Crossref","is-referenced-by-count":12,"title":["Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy"],"prefix":"10.1093","volume":"61","author":[{"given":"Ankoor","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Oncology, University of Calgary , Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Woolson","sequence":"additional","affiliation":[{"name":"Rho Federal System , Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Pinckney","sequence":"additional","affiliation":[{"name":"Rho Federal System , Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette","family":"Keyes-Elstein","sequence":"additional","affiliation":[{"name":"Rho Federal System , Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Oncology, Roswell Park Comprehensive Cancer Center , Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D","family":"Sempowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McSweeney","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Colorado Blood Cancer Institute , Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen D","family":"Mayes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Texas , Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Crofford","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E","family":"Csuka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin , Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan , Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Simms","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dartmouth-Hitchcock Medical Center , Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia , Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"LeClercq","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Oncology, University of Calgary , Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William St","family":"Clair","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B","family":"Nixon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nash","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Colorado Blood Cancer Institute , Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wener","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fred Hutchinson Cancer Research Center"},{"name":"Department of Medicine, University of Washington , Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Brasington","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University , St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Silver","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina , Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M","family":"Griffith","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-2373","authenticated-orcid":false,"given":"Daniel E","family":"Furst","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington , Seattle, WA"},{"name":"Department of Medicine, University of California , Los Angeles, CA, USA"},{"name":"University of Florence , Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Goldmuntz","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"2022100812081730100_keac015-B1","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022100812081730100_keac015-B2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The pathogenesis of systemic sclerosis","volume":"6","author":"Katsumoto","year":"2011","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2022100812081730100_keac015-B3","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2022100812081730100_keac015-B4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1006\/jaut.1993.1059","article-title":"Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL\/6 Pa\/Pa mice","volume":"6","author":"Phelps","year":"1993","journal-title":"J Autoimmun"},{"key":"2022100812081730100_keac015-B5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"Pt A","key":"2022100812081730100_keac015-B6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0091-679X(01)63015-2","article-title":"Chapter 11 Cell preparation for the identification of leukocytes","volume":"63","author":"Stewart","year":"2001","journal-title":"Methods Cell Biol"},{"key":"2022100812081730100_keac015-B7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0091-679X(01)64019-6","article-title":"Multiparameter data acquisition and analysis of leukocytes by flow cytometry","volume":"64","author":"Stewart","year":"2001","journal-title":"Methods Cell Biol"},{"key":"2022100812081730100_keac015-B8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cyto.b.20446","article-title":"Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients","volume":"76","author":"Grant","year":"2009","journal-title":"Cytometry B Clin Cytom"},{"key":"2022100812081730100_keac015-B9","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1016\/B978-0-12-386456-7.07104-5","volume-title":"Pathobiology of human disease: a dynamic encyclopedia of disease mechanisms","author":"Tario","year":"2014"},{"key":"2022100812081730100_keac015-B10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"2022100812081730100_keac015-B11","first-page":"1","article-title":"Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis","volume":"23","author":"Fox","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2022100812081730100_keac015-B12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.autrev.2010.08.003","article-title":"Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis","volume":"10","author":"Baraut","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2022100812081730100_keac015-B13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.24432","article-title":"Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis","volume":"60","author":"Fuschiotti","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022100812081730100_keac015-B14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L","article-title":"Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis","volume":"42","author":"Atamas","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2022100812081730100_keac015-B15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.23406","article-title":"T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease","volume":"58","author":"Boin","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022100812081730100_keac015-B16","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3486","article-title":"Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease","volume":"13","author":"Truchetet","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2022100812081730100_keac015-B17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00296-019-04350-4","article-title":"B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis","volume":"39","author":"Antonopoulos","year":"2019","journal-title":"Rheumatol Int"},{"key":"2022100812081730100_keac015-B18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/art.37860","article-title":"Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement","volume":"65","author":"Truchetet","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022100812081730100_keac015-B19","first-page":"283","article-title":"Reduced circulating natural killer T cells and gamma\/delta T cells in patients with systemic sclerosis","volume":"32","author":"Riccieri","year":"2005","journal-title":"J Rheumatol"},{"key":"2022100812081730100_keac015-B20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/ard.49.1.40","article-title":"Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis","volume":"49","author":"Gustafsson","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"2022100812081730100_keac015-B21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.54.1.69","article-title":"Natural killer cells and gamma delta T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies","volume":"54","author":"Holcombe","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2022100812081730100_keac015-B22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2249.2004.02647.x","article-title":"T cell repertoire in patients with stable scleroderma","volume":"139","author":"Tiev","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"2022100812081730100_keac015-B23","first-page":"2003","article-title":"Resistance to apoptosis in circulating alpha\/beta and gamma\/delta T lymphocytes from patients with systemic sclerosis","volume":"33","author":"Cipriani","year":"2006","journal-title":"J Rheumatol"},{"key":"2022100812081730100_keac015-B24","doi-asserted-by":"crossref","DOI":"10.1002\/acr.24785","article-title":"Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data","author":"Keyes-Elstein","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac015\/42396063\/keac015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/4155\/46382704\/keac015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/4155\/46382704\/keac015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T15:29:42Z","timestamp":1726586982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/10\/4155\/6520419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,2,2]]},"published-print":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac015","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,2,2]]}}}